Published in J Hepatol on January 01, 2003
L-ornithine L-aspartate in Overt Hepatic Encephalopathy (HEAL) | NCT01722578
Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ (2004) 1.64
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol (2010) 1.50
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci (2007) 1.35
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J (2005) 1.17
High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol (2012) 1.15
Pathogenesis, diagnosis, and treatment of hepatic encephalopathy. J Clin Exp Hepatol (2011) 0.94
Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis. Gastroenterol Res Pract (2013) 0.90
Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag (2009) 0.90
Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol (2015) 0.88
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol (2012) 0.87
Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World J Gastroenterol (2012) 0.85
Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. Am J Gastroenterol (2015) 0.85
Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis (2013) 0.85
Update on the management of cirrhosis - focus on cost-effective preventative strategies. Clinicoecon Outcomes Res (2013) 0.84
Sodium benzoate for treatment of hepatic encephalopathy. Gastroenterol Hepatol (N Y) (2013) 0.82
Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therap Adv Gastroenterol (2011) 0.81
Management in acute liver failure. J Clin Exp Hepatol (2014) 0.79
Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol (2015) 0.79
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Ther Clin Risk Manag (2009) 0.79
Challenges of designing hepatic encephalopathy treatment trials. Hepatology (2003) 0.78
Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats. World J Gastroenterol (2012) 0.78
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol (2015) 0.77
Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology (2017) 0.77
Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose. Saudi J Gastroenterol (2011) 0.77
Is oral L-acyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature. Dig Dis Sci (2008) 0.76
Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy. Gastroenterol Hepatol (N Y) (2016) 0.76
Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Am J Ther (2014) 0.76
Rifaximin in the treatment of hepatic encephalopathy. Hepat Med (2011) 0.76
Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology. Gastroenterol Hepatol (N Y) (2006) 0.75
Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y) (2006) 0.75
Managing complications in cirrhotic patients. United European Gastroenterol J (2015) 0.75
Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol (2015) 0.75
Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. ISRN Hepatol (2014) 0.75
Management of overt hepatic encephalopathy. J Clin Exp Hepatol (2014) 0.75
Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence (2014) 0.75
Pathophysiology, diagnosis, and management of hepatic encephalopathy. Inflammopharmacology (2014) 0.75
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Role of a research ethics committee in follow-up and publication of results. Lancet (2003) 3.61
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol (2007) 3.21
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology (2007) 3.19
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (2002) 2.86
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology (2002) 2.34
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology (2002) 2.12
[A secure job for ever]. Med Clin (Barc) (2003) 2.01
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology (2006) 1.96
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Hepatorenal syndrome. Lancet (2003) 1.86
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl (2006) 1.77
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (2003) 1.64
Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology (2014) 1.60
MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology (2005) 1.58
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J (2006) 1.50
[Organization and functioning model of biomedical research structures. Situation and future challenges]. Med Clin (Barc) (2008) 1.46
[Deaths by a medical resident. Could they have been avoided?]. Med Clin (Barc) (2003) 1.38
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (2015) 1.36
Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology (2002) 1.35
Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology (2005) 1.35
Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology (2006) 1.31
Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology (2010) 1.29
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology (2008) 1.21
Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology (2004) 1.18
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol (2009) 1.14
Bacterial infections in cirrhosis. Liver Int (2004) 1.06
Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology (2003) 1.05
Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics. Alcohol Clin Exp Res (2005) 1.04
Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol (2003) 1.02
Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology (2005) 1.01
Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol (2005) 1.01
Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology (2003) 1.00
Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology (2010) 1.00
N-Acetyl-cysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. J Hepatol (2004) 0.99
Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol (2004) 0.97
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol (2003) 0.96
Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol (2002) 0.96
Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses (2004) 0.96
High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol (2002) 0.95
Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients. Liver Int (2006) 0.94
Natural history of primary biliary cirrhosis. Clin Liver Dis (2003) 0.94
T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol (2011) 0.91
Clinical significance of occult hepatitis B virus infection. World J Gastroenterol (2011) 0.90
Increased apoptosis dependent on caspase-3 activity in polymorphonuclear leukocytes from patients with cirrhosis and ascites. J Hepatol (2004) 0.90
Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology (2003) 0.89
Are angiotensin II receptor antagonists useful strategies in steatotic and nonsteatotic livers in conditions of partial hepatectomy under ischemia-reperfusion? J Pharmacol Exp Ther (2008) 0.89
Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol (2004) 0.89
Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med (2004) 0.88
Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2010) 0.88
Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol (2011) 0.88
Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology (2003) 0.88
Microarray analysis of endothelial differentially expressed genes in liver of cirrhotic rats. Gastroenterology (2005) 0.87
Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol (2003) 0.87
Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol (2008) 0.87
Addition of carvedilol to University Wisconsin solution improves rat steatotic and nonsteatotic liver preservation. Liver Transpl (2010) 0.87
Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol (2003) 0.87
Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain. Am J Gastroenterol (2004) 0.86
Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci (2007) 0.86
p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol (2003) 0.86
Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther (2006) 0.86
Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology (2002) 0.86
Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol (2010) 0.85
Enterococcus gallinarum bacteriascites in a patient with active tuberculosis and HCV cirrhosis. Am J Gastroenterol (2002) 0.84
Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury. Crit Care Med (2008) 0.83
Psychosocial adjustment to orthotopic liver transplantation in 266 recipients. Liver Transpl (2004) 0.83
[Neurocysticercosis diagnosis and management in Peru]. Rev Peru Med Exp Salud Publica (2011) 0.83
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther (2008) 0.83
5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology (2002) 0.82
Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol (2005) 0.82
[Non-alcoholic steatohepatitis]. Med Clin (Barc) (2003) 0.82
Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther (2006) 0.81
Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol (2003) 0.81
Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl (2012) 0.81
Improved rat steatotic and nonsteatotic liver preservation by the addition of epidermal growth factor and insulin-like growth factor-I to University of Wisconsin solution. Liver Transpl (2010) 0.80
Insulin-like growth factor and epidermal growth factor treatment: new approaches to protecting steatotic livers against ischemia-reperfusion injury. Endocrinology (2009) 0.80
Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. Liver Int (2007) 0.80
Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci (2002) 0.80
Adiponectin and resistin protect steatotic livers undergoing transplantation. J Hepatol (2013) 0.80